Thermo Fisher Scientific (TMO)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$516.48-0.22%
Close 2026-07-07 · 1-day change
Reading TMO? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TMO free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading TMO? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TMO free→QuarterlyIQ Insights · TMO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On April 23, 2026, the Registrant announced its financial results for the fiscal quarter ended March 28, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") o…
Other Events. On March 24, 2026, Thermo Fisher Scientific Inc. (“Thermo Fisher”) issued a press release announcing the completion of its acquisition of Clario Holdings, Inc. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Other Events. The sale of the Notes was made pursuant to the terms of an Underwriting Agreement, which the Company entered into on February 9, 2026 (the “Underwriting Agreement”), with Deutsche Bank Securities Inc., RBC Capital Markets, LLC, SMBC Nikko Securities America, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named in Schedule A to the Underwriting Agreement. The Company expects that the net proceeds from the sale of the Notes will be approximate…
Entry into a Material Definitive Agreement. On February 12, 2026, Thermo Fisher Scientific Inc. (the “Company”) issued $1,000,000,000 aggregate principal amount of 4.215% Senior Notes due 2031 (the “2031 Notes”), $750,000,000 aggregate principal amount of 4.550% Senior Notes due 2033 (the “2033 Notes”), $1,300,000,000 aggregate principal amount of 4.902% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 aggregate principal amount of 5.546% Senior Notes due 2046 (the “2046 Notes” and,…
Results of Operations and Financial Condition. On January 29, 2026, the Registrant announced its financial results for the fiscal quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Ex…
Executive Vice President and Chief Operating Officer — Michel Lagarde: Mr. Lagarde is leaving the company to pursue other opportunities.
Entry into a Material Definitive Agreement. On December 1, 2025, Thermo Fisher Scientific (Finance I) B.V. (“Thermo Fisher International”), an indirect, wholly-owned finance subsidiary of Thermo Fisher Scientific Inc. (the “Company”), issued €1,000,000,000 aggregate principal amount of Floating Rate Senior Notes due 2027 (the “Floating Rate Notes”) and €1,100,000,000 aggregate principal amount of 3.628% Senior Notes due 2035 (the “Fixed Rate Notes” and, together with the Floating Rate Notes,…
Other Events. The sale of the Securities was made pursuant to the terms of an Underwriting Agreement, dated November 24, 2025 (the “Underwriting Agreement”), among Thermo Fisher International, as issuer, the Company, as parent guarantor, and Barclays Bank PLC, BNP PARIBAS, HSBC Continental Europe Morgan Stanley & Co. International plc, as lead managers of the several underwriters named in Schedule A to the Underwriting Agreement. The Company expects that the net proceeds from the sale of the…
Other Events On October 29, 2025, Thermo Fisher Scientific Inc. (“Thermo Fisher”) issued a press release announcing the execution of a definitive agreement to acquire Clario Holdings, Inc. (“Clario”) for approximately $8.875 billion in cash at the closing of the transaction, with an additional $125 million in deferred consideration and up to $400 million in contingent consideration to be payable following the closing. The transaction is expected to be completed by the middle of 2026 and is su…
Results of Operations and Financial Condition. On October 22, 2025, the Registrant announced its financial results for the fiscal quarter ended September 27, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange A…
Other Events. The sale of the Notes was made pursuant to the terms of an Underwriting Agreement, which the Company entered into on September 30, 2025 (the “Underwriting Agreement”), with J.P. Morgan Securities LLC, ING Financial Markets LLC, Mizuho Securities USA LLC and Scotia Capital (USA) Inc., as representatives of the several underwriters named in Schedule A to the Underwriting Agreement. The Company expects that the net proceeds from the sale of the Notes will be approximately $2.48 bil…
Entry into a Material Definitive Agreement. On October 7, 2025, Thermo Fisher Scientific Inc. (the “Company”) issued $500,000,000 aggregate principal amount of 4.200% Senior Notes due 2031 (the “2031 Notes”), $750,000,000 aggregate principal amount of 4.473% Senior Notes due 2032 (the “2032 Notes”), $750,000,000 aggregate principal amount of 4.794% Senior Notes due 2035 (the “2035 Notes”) and $500,000,000 aggregate principal amount of 4.894% Senior Notes due 2037 (the “2037 Notes” and, collec…
Other Events. On September 2, 2025, Thermo Fisher Scientific Inc. (“Thermo Fisher”) issued a press release announcing the completion of its acquisition of Solventum Corporation’s purification and filtration business. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
CFO — Stephen Williamson: Stephen Williamson is retiring as CFO, and James R. Meyer has been appointed to succeed him.
Results of Operations and Financial Condition. On July 23, 2025, the Registrant announced its financial results for the fiscal quarter ended June 28, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or…
Chairman, President and Chief Executive Officer (CEO) — Marc N. Casper: Grant of a long-term performance-based restricted stock unit award to secure continued leadership and drive shareholder returns.
Results of Operations and Financial Condition. On April 23, 2025, the Registrant announced its financial results for the fiscal quarter ended March 29, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") o…
Other Events On February 25, 2025, Thermo Fisher Scientific Inc. (“Thermo Fisher”) and Solventum Corporation (“Solventum”) entered into an agreement, pursuant to which, subject to the satisfaction or waiver of specified conditions, Thermo Fisher agreed to acquire Solventum’s purification and filtration business for approximately $4.1 billion in cash. The transaction is expected to be completed by the end of 2025 and is subject to customary closing conditions and regulatory approvals. Forward-…
Director — Karen S. Lynch: The Board of Directors elected Karen S. Lynch as a new director.
Results of Operations and Financial Condition. On January 30, 2025, the Registrant announced its financial results for the fiscal quarter and year ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Ex…
Results of Operations and Financial Condition. On October 23, 2024, the Registrant announced its financial results for the fiscal quarter ended September 28, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange A…
Results of Operations and Financial Condition. On July 24, 2024, the Registrant announced its financial results for the fiscal quarter ended June 29, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or…
Results of Operations and Financial Condition. On April 24, 2024, the Registrant announced its financial results for the fiscal quarter ended March 30, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") o…
Results of Operations and Financial Condition On January 31, 2024, the Registrant announced its financial results for the fiscal quarter and year ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exc…
Other Events. The sale of the Notes was made pursuant to the terms of an Underwriting Agreement, which the Company entered into on November 28, 2023 (the “Underwriting Agreement”), with BofA Securities, Inc., Morgan Stanley & Co. LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named in Schedule A to the Underwriting Agreement. The Company expects that the net proceeds from the sale of the Notes will be approximately $2.48 bil…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.